Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium
Authors:
- Rachel M. HuckfeldtRHRachel M. Huckfeldt
- Demetrios G. VavvasDVDemetrios G. Vavvas
- 1 October 2019
- journal article
- research article
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 50 (10) , 656-659
Abstract
A pigmentary maculopathy associated with chronic use of the drug pentosan polysulfate sodium (PPS) was recently described. The authors present a case of PPS-associated maculopathy that continued to progress for 6 years after discontinuation of this medication. [ Ophthalmic Surg Lasers Imaging Retina . 2019;50:656–659.]Keywords
This publication has 8 references indexed in Scilit:
- SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUGRetina, 2019
- Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate SodiumOphthalmology, 2018
- FDA BRUDAC 2018 Criteria for Interstitial Cystitis/Bladder Pain Syndrome Clinical Trials: Future Direction for ResearchJournal of Urology, 2018
- Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome: AUA Guideline AmendmentJournal of Urology, 2015
- Pentosan Polysulfate Sodium for Treatment of Interstitial Cystitis/Bladder Pain Syndrome: Insights from a Randomized, Double-Blind, Placebo Controlled StudyJournal of Urology, 2015
- Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencingGenetics in Medicine, 2014
- Progressive hydroxychloroquine toxicity mimicking low‐tension glaucoma after discontinuation of the drugActa Ophthalmologica, 2010
- Successful Treatment of Interstitial Cystitis with Sodium pentosanpolysulfateJournal of Urology, 1983